361 related articles for article (PubMed ID: 17164822)
41. Neural mechanisms of the reinforcing action of cocaine.
Wise RA
NIDA Res Monogr; 1984; 50():15-33. PubMed ID: 6440023
[TBL] [Abstract][Full Text] [Related]
42. Monoamine neurocircuitry in depression and strategies for new treatments.
Hamon M; Blier P
Prog Neuropsychopharmacol Biol Psychiatry; 2013 Aug; 45():54-63. PubMed ID: 23602950
[TBL] [Abstract][Full Text] [Related]
43. The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction.
Zaniewska M; Filip M; Przegalinski E
Curr Neuropharmacol; 2015; 13(3):407-18. PubMed ID: 26411968
[TBL] [Abstract][Full Text] [Related]
44. Cocaine reward and cocaine craving: the role of dopamine in perspective.
Wise RA
NIDA Res Monogr; 1994; 145():191-206. PubMed ID: 8742814
[No Abstract] [Full Text] [Related]
45. Difference in magnitude of psychostimulant-induced extracellular norepinephrine in the ventral tegmental area contributes to discrepant prefrontal dopamine outflow.
Pan WH; Hsieh MC; Wu HH; Lin SK
Addict Biol; 2007 Mar; 12(1):51-8. PubMed ID: 17407497
[TBL] [Abstract][Full Text] [Related]
46. The opioid receptors as targets for drug abuse medication.
Noble F; Lenoir M; Marie N
Br J Pharmacol; 2015 Aug; 172(16):3964-79. PubMed ID: 25988826
[TBL] [Abstract][Full Text] [Related]
47. Cross-talk between dopaminergic and noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus.
Guiard BP; El Mansari M; Blier P
Mol Pharmacol; 2008 Nov; 74(5):1463-75. PubMed ID: 18703671
[TBL] [Abstract][Full Text] [Related]
48. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?
Pierce RC; Kumaresan V
Neurosci Biobehav Rev; 2006; 30(2):215-38. PubMed ID: 16099045
[TBL] [Abstract][Full Text] [Related]
49. The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description.
Paterson LM; Flechais RS; Murphy A; Reed LJ; Abbott S; Boyapati V; Elliott R; Erritzoe D; Ersche KD; Faluyi Y; Faravelli L; Fernandez-Egea E; Kalk NJ; Kuchibatla SS; McGonigle J; Metastasio A; Mick I; Nestor L; Orban C; Passetti F; Rabiner EA; Smith DG; Suckling J; Tait R; Taylor EM; Waldman AD; Robbins TW; Deakin JF; Nutt DJ; Lingford-Hughes AR;
J Psychopharmacol; 2015 Sep; 29(9):943-60. PubMed ID: 26246443
[TBL] [Abstract][Full Text] [Related]
50. Alterations in the levels of heterotrimeric G protein subunits induced by psychostimulants, opiates, barbiturates, and ethanol: Implications for drug dependence, tolerance, and withdrawal.
Kitanaka N; Kitanaka J; Hall FS; Tatsuta T; Morita Y; Takemura M; Wang XB; Uhl GR
Synapse; 2008 Sep; 62(9):689-99. PubMed ID: 18566973
[TBL] [Abstract][Full Text] [Related]
51. Sex differences in neural mechanisms mediating reward and addiction.
Becker JB; Chartoff E
Neuropsychopharmacology; 2019 Jan; 44(1):166-183. PubMed ID: 29946108
[TBL] [Abstract][Full Text] [Related]
52. Drug abuse and the neurovascular unit.
Egleton RD; Abbruscato T
Adv Pharmacol; 2014; 71():451-80. PubMed ID: 25307226
[TBL] [Abstract][Full Text] [Related]
53. [Principles of the pharmacological treatment of drug addiction].
Saadan M; Scuvée-Moreau J; Seutin V
Rev Med Liege; 2013; 68(5-6):245-51. PubMed ID: 23888572
[TBL] [Abstract][Full Text] [Related]
54. New concepts in cocaine addiction: the dopamine depletion hypothesis.
Dackis CA; Gold MS
Neurosci Biobehav Rev; 1985; 9(3):469-77. PubMed ID: 2999657
[TBL] [Abstract][Full Text] [Related]
55. Expression of immediate early genes in brain reward circuitries: Differential regulation by psychostimulant and opioid drugs.
Bisagno V; Cadet JL
Neurochem Int; 2019 Mar; 124():10-18. PubMed ID: 30557593
[TBL] [Abstract][Full Text] [Related]
56. Galanin: a novel therapeutic target for depression, anxiety disorders and drug addiction?
Holmes A; Picciotto MR
CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):225-32. PubMed ID: 16611095
[TBL] [Abstract][Full Text] [Related]
57. Substance use disorder a bio-directional subset of reward deficiency syndrome.
Blum K; Gold M; Demetrovics Z; Archer T; Thanos PK; Baron D; Badgaiyan RD
Front Biosci (Landmark Ed); 2017 Jun; 22(9):1534-1548. PubMed ID: 28410131
[TBL] [Abstract][Full Text] [Related]
58. Heterogeneous dopamine signals support distinct features of motivated actions: implications for learning and addiction.
Saddoris MP; Siletti KA; Stansfield KJ; Bercum MF
Learn Mem; 2018 Sep; 25(9):416-424. PubMed ID: 30115763
[TBL] [Abstract][Full Text] [Related]
59. Parallel roles for dopamine in pathological gambling and psychostimulant addiction.
Zack M; Poulos CX
Curr Drug Abuse Rev; 2009 Jan; 2(1):11-25. PubMed ID: 19630734
[TBL] [Abstract][Full Text] [Related]
60. Addiction and withdrawal--current views.
Melichar JK; Daglish MR; Nutt DJ
Curr Opin Pharmacol; 2001 Feb; 1(1):84-90. PubMed ID: 11712541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
